Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents

Oncology

Volumn 77, Issue 6, 2010, Pages 358-365

  Noberasco, Cristina ^a   Spitaleri, Gianluca ^a   Mancuso, Patrizia ^b   Zorzino, Laura ^c   Radice, Davide ^d   Milani, Alessandra ^a   Rocca, Andrea ^e   Bertolini, Francesco ^b   Sandri, Maria Teresa ^c   Curigliano, Giuseppe ^a   De Pas, Tommaso ^a   Jemos, Costantino ^a   Omodeo Salè, Emanuela ^a   Boselli, Sabrina ^a   De Braud, Filippo ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b Division of Hematology Oncology   (Italy)

^c Division of Laboratory Medicine and Pathology   (Italy)

^d Division of Epidemiology and Biostatistics   (Italy)

^e Division of Medical Oncology   (Italy)

Author keywords

Anti angiogenic treatment; Celecoxib; Circulating endothelial cells; Interferon; Solid tumours; Thalidomide; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; CELECOXIB; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THALIDOMIDE; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CARCINOID; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENDOTHELIUM CELL; HUMAN; KIDNEY CARCINOMA; LETHARGY; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MELANOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; DRUG EFFECT; NEOPLASM; PHYSIOLOGY; STEM CELL; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ENDOTHELIAL CELLS; HUMANS; NEOPLASMS; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 73649149422     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000275830     Document Type: Article

References (39)

1. Folkman J: Tumor angiogenesis therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. (Pubitemid 38702844)
3. Ratain MJ, Eisen T, Stadler WM, et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512. (Pubitemid 46630627)
4. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124. (Pubitemid 46089672)
5. Taylor KL, Oates RK, Grane R, et al: IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas. J Interferon Cytokine Res 2006; 26: 353-361. (Pubitemid 43801017)
6. Slaton JW, Perrotte P, Inoue K, et al: Interferon-mediated down-regulation of angiogenesis related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-2734. (Pubitemid 29493945)
7. Perrone G, Santini D, Verzi A, et al: COX-2 expression in ampullary carcinoma: correlation with angiogenesis process and clinicopathological variables. J Clin Pathol 2006; 59: 492-496. (Pubitemid 44367975)
8. Krysan K, Reckamp KL, Sharma S, Dubinett SM: The potential and rationale for COX-2 inhibitors in lung cancer. Anticancer Agents Med Chem 2006; 6: 209-220. (Pubitemid 43796639)
9. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952. (Pubitemid 30419089)
10. Dimopoulos MA, Eleutherakis-Papaiakovou V: Adverse effects of thalidomide administration in patients with neoplastic diseases. Am J Med 2004; 117: 508-515. (Pubitemid 39349589)
11. Fanelli M, Sarmiento R, Gattuso D, et al: Thalidomide: a new anticancer drug? Expert Opin Investig Drugs 2003; 12: 1211-1225. (Pubitemid 36857209)
12. D'Amato RJ, Loughnan MS, Flynn E, et al: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91: 4082-4085. (Pubitemid 24139577)
13. Baidas SM, Winer EP, Fleming GF, et al: Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol 2000; 18: 2710-2717. (Pubitemid 30463553)
14. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-2734. (Pubitemid 29493945)
15. Bauer JA, Morrison BH, Grane RW, et al: IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis. J Interferon Cytokine Res 2003; 23: 3-10.
16. Hernberg M, Virkkunen P, Bono P, et al: Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003; 21: 3770-3776. (Pubitemid 46606231)
17. Clark PE, Hall MC, Miller A, et al: Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 2004; 63: 1061-1065. (Pubitemid 38746803)
18. Schwartz JD, Sung M, Schwartz M, et al: Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon- alpha2a upon progression. Oncologist 2005; 10: 718-727. (Pubitemid 41567284)
19. Mancuso P, Burlini A, Pruneri G, et al: Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001; 97: 3658-3661. (Pubitemid 33781395)
20. Monestiroli S, Mancuso P, Burlini A, et al: Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res 2001; 61: 4341-4344. (Pubitemid 32685756)
21. Mancuso P, Colleoni M, Calleri A, et al: Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452-459. (Pubitemid 44061341)
22. Rabascio C, Muratori E, Mancuso P, et al: Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res 2004; 64: 4373-4377. (Pubitemid 38802446)
23. St Croix B, Rago C, Velculescu V, et al: Genes expressed in human tumor endothelium. Science 2000; 289: 1197-1202. (Pubitemid 30650733)
24. Colleoni M, Rocca A, Sandri MT, et al: Lowdose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002; 13: 73-80. (Pubitemid 34436728)
25. CONSORT guidelines. http://www.consortstatement. org (last accessed 16/01/2008).
26. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
27. Common Toxicity Criteria Version 2.0. http://ctep.cancer.gov/forms/ CTCv20-4- 30-992.pdf. Publication date: April 30, 1999 (last accessed 14/07/2008).
28. Hyodo I, Doi T, Endo H, et al: Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34: 2041-2045. (Pubitemid 28546939)
29. Philpott NJ, Turner AJ, Scopes J, et al: The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood 1996; 87: 2244-2251. (Pubitemid 26086863)
30. R Development Core Team (2006): R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing. http://www.R-project.org.
31. Dellapasqua S, Bertolini F, Bagnardi V, et al: Metronomic cyclophosphamide and ca pecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26: 4899-4905.
32. Torrisi R, Bagnardi V, Cardillo A, et al: Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. Br J Cancer 2008; 99: 1564-1571.
33. Willett CG, Boucher Y, di Tomaso E, et al: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-147. (Pubitemid 38524883)
34. Yee KW, Hagey A, Verstovsek S, et al: Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005; 11: 6615-6624. (Pubitemid 41339002)
35. Beaudry P, Force J, Naumov GN, et al: Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 2005; 11: 3514-3522. (Pubitemid 40627906)
36. Beerepoot LV, Radema SA, Witteveen EO, et al: Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006; 24: 1491-1498.
37. Li H, Raia V, Bertolini F, Price DK, Figg WD: Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU Int 2008; 101: 884-888. (Pubitemid 351347717)
38. Escudier B, Pluzanska A, Koralewski P, et al: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-2111. (Pubitemid 350296300)
39. Llovet JM, Ricci S, Mazzaferro V, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.